H.R. 1843 119th Congress House

To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

Introduced: March 5, 2025 Introduced by: Neal P. Dunn Republican · Florida See on congress.gov

Health

Everywhere this bill has been 2 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Mar 5, 2025

Referred to the House Committee on Energy and Commerce.

Mar 5, 2025

Introduced in House

Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

What's happening now March 5, 2025

Referred to the House Committee on Energy and Commerce.

Plain-English summary Congressional Research Service

This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.

Hearings & markups 1

Markup of Seven Bills
Markup Sep 17, 2025 · 10:00 AM EDT · Energy and Commerce Committee

Related & companion bills 4

Bill text 1 version

Introduced in House Formatted Text PDF Formatted XML

Source documents hosted by congress.gov.

Committees of jurisdiction 1

Energy and Commerce Committee
House of Representatives

Lobbying activity 82

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

BCBSM, INC.
for BCBSM INC · Minnesota · 3rd Quarter 2026 (July 1 - Sep 30)
BLUE CROSS AND BLUE SHIELD OF KANSAS, INC.
for BLUE CROSS AND BLUE SHIELD OF KANSAS INC · Kansas · 3rd Quarter 2026 (July 1 - Sep 30)
BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC.
for BLUE CROSS AND BLUE SHIELD OF FLORIDA INC · Florida · 3rd Quarter 2026 (July 1 - Sep 30)
BLUE CROSS AND BLUE SHIELD ASSOCIATION
for BLUE CROSS AND BLUE SHIELD ASSOCIATION · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
BLUE CROSS BLUE SHIELD OF MICHIGAN
for BLUE CROSS BLUE SHIELD OF MICHIGAN · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
GUIDEWELL MUTUAL HOLDING CORPORATION
for GUIDEWELL MUTUAL HOLDING CORPORATION · Florida · 3rd Quarter 2026 (July 1 - Sep 30)

Bodies those filers lobbied

HOUSE OF REPRESENTATIVES
80 filings
SENATE
80 filings
Health & Human Services, Dept of (HHS)
34 filings
Centers For Medicare and Medicaid Services (CMS)
33 filings
White House Office
21 filings
Office of Management & Budget (OMB)
18 filings
Executive Office of the President (EOP)
15 filings
Labor, Dept of (DOL)
15 filings

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.

See all 82 filings →

Cosponsors 1

Mullin, Kevin

California · Mar 5, 2025

Cite this page click to expand

APA

U.S. Congress. (2026). H.R. 1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.. 119th Congress. Open America. https://openamerica.io/bill/119-HR-1843/

MLA

"H.R. 1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-HR-1843/.

Bluebook (legal)

H.R. 1843, 119th Cong. (2026), https://openamerica.io/bill/119-HR-1843/.

Markdown link

[H.R. 1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.](https://openamerica.io/bill/119-HR-1843/)